Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ME2 | P23368 | 1/20 | 0.34 |
| ▸ | ME1 | P48163 | 1/20 | 0.34 |
| ▸ | ME3 | Q16798 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176012 | 0.91 | GRM5 (0.38) | RORCGRM5HSD17B10ALDH1A1KMT2A | |
| SCHEMBL3590902 | 0.91 | GPR119 (0.44) | KMT2AMAPT | |
| SCHEMBL105484 | 0.86 | HTR1A (0.42) | — | |
| SCHEMBL3601001 | 0.80 | IDO1 (0.37) | RORCALDH1A1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL106074 | 0.77 | GAA (0.42) | RAB9AKMT2A | |
| SCHEMBL132842 | 0.72 | GRM5 (0.42) | RORCGRM5ALDH1A1 | |
| SCHEMBL106403 | 0.70 | RORC (0.39) | RORCGRM5ALDH1A1KMT2APOLB | |
| SCHEMBL106404 | 0.70 | RORC (0.39) | RORCGRM5ALDH1A1KMT2APOLB | |
| SCHEMBL103238 | 0.68 | HTT (0.38) | USP2NPSR1HSD17B10ALDH1A1KMT2A | |
| SCHEMBL105867 | 0.65 | TACR1 (0.45) | RORCGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | RORC 19/4885GRM5 1608/4885USP2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.